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Gastric cancer is one of the leading causes of cancer death world-wide and carries a high rate of metastatic risk. In
addition to other protein-coding oncogenes and tumor suppressor genes, microRNAs play an important role in
gastric cancer tumorigenic progression. Here, we show that miR-206 is expressed at markedly low levels in a cohort
of gastric tumors compared to their matching normal tissues, and in
a number of gastric cancer cell lines. Down-regulation of miR-206 was particularly significant in tumors with
lymphatic metastasis, local invasion, and advanced TNM staging. We find that forced expression of miR-206
suppressed the proliferation, colony-formation, and xenograft tumorigenesis of SCG-7901 cells, a line of gastric
cancer cells. Forced expression of miR-206 also suppressed SCG-7901 cell migration and invasion, as well as
metastasis in cell culture or tail-vein injected mouse models, respectively. The anti-metastatic effect of miR-206 is
likely mediated by targeting metastasis regulatory genes STC2, HDAC4, KLF4, IGF1R, FRS2, SFRP1, BCL2, BDNF, and
K-ras, which were drastically down-regulated by stable expression of exogenous miR-206 in SCG-7901 cells. Taken
together, our results indicate that miR-206 is a tumor suppressor of gastric cancer acting at steps that regulate
metastasis.
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Gastric cancer (GC) ranks the fourth most common
cancer and the second leading cause of cancer-related
death worldwide [1]. The prognosis for patients with
advanced gastric cancer is poor, despite recent improve-
ments in gastriectomy, chemotherapy, and radiotherapy
[2]. Since GC is a polygenic disease arising as the result
of multiple gene dysregulations, elucidation of the regu-
latory network governing GC tumorigenesis is impera-
tive for developing novel targeted therapies.
Tumorigenesis in the stomach is a multistep process that
entails genetic and epigenetic alterations of protein-coding
as well as non-coding proto-oncogenes and tumor-sup-
pressor genes. Interactions among host, environmental
and bacterial factors also influence the disease progress.
Helicobacter pylori (HP) infection has been established as
a major risk factor for GC; the two histological subtypes of* Correspondence: drtanglm@njmu.edu.cn; sycheng@njmu.edu.cn
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unless otherwise stated.gastric cancer, the intestinal and the diffuse subtypes, are
both associated with HP infection, which contributes to
more than 80% of cases [3], especially in antral/body gas-
tric cancer [4]. Mechanistically, HP infection was found to
cause a twofold increase in EGF and EGFR in gastric an-
tral biopsy tissues, but its eradication reduces the levels of
both factors to those of the controls [5]. HP infection in
patients with chronic gastritis is also significantly associa-
ted with down-regulation of E-cadherin due to increased
promoter methylation [6], whereas eradication HP signifi-
cantly reduced the levels of MMP-9, a metalloproteinase
positively associated with tumor invasion and metastasis
[7], in the antrum and the corpus mucosa [8].
In addition to HP infection, there is a multitude of
causes leading to aberrant gene expression in gastric can-
cer, and the mechanism of gastric cancer metastasis is very
complex as well. The Ras-dependent MAPK signaling,
which eventually leads to increased proliferation in gastric
cancer and is mainly caused by aberrations of K-ras acti-
vation, is frequently associated with the intestinal-type
gastric cancer [9]. Stanniocalcin 2 (STC2), a secreted
glycoprotein with important functions in calcium and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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high levels cancerous gastric tissues, lymph node metas-
tasis, and venous invasion [10]. The 5-year survival rate
was significantly lower in patients with STC2 expression
compared to patients without STC2 expression [11].
BDNF (Brain-derived neutrophic factor) expression was
reported to show significantly increased expression in
gastric cancer tissue compared to adjacent normal mu-
cosa, and high levels of BDNF at the invasive front were
correlated to vessel invasion, lymph node metastasis,
peritoneal dissemination, and poor prognosis in gastric
cancer patients [12]. Despite the progress in identifying
the above regulatory genes, the precise underlying me-
chanism causing GC metastasis still remains to be
determined.
Dysregulations of microRNAs play very important
roles in tumorigenesis. The role of microRNAs in gas-
tric cancer tumorigenesis has been well documented.
Here, we focus on miR-206, which along with its closely
related paralogs miR-1, 133a, and miR-133b, plays very
important roles in muscle differentiation. These four
microRNAs are highly conserved in sequence and gen-
omic organization, and are called myomiRs because
they were found to be expressed at high levels in the
muscles [13]. MiR-1-1/miR-133a-2, miR-1-2/miR-133a-1,
and miR-206/miR-133b form clusters in three different
chromosomal regions in the human genome 20q13.33,
18q11.2, and 6p12.2, respectively. However, these miRNAs
can act as tumor suppressors in various human cancers
[14]; for instance, miR-1 and miR-133a were found to be
frequently down-regulated in bladder cancers, and sup-
press tumor growth by targeting TAGLN2 [15]. MiR-1
and miR-206 were shown to possess similar tumor-sup-
pressor roles in rhabdomyosarcoma through blocking
c-Met expression [16]. MiR-206 was also reported to act
as a tumor-suppressor in breast cancer [17], and lung
cancer [18]. We report here that miR-206 expression is
inversely associated with lymphatic metastasis, local inva-
sion, and the TNM malignancy staging of GC, and force




Surgically resected human gastric cancer and adjacent
non-tumor tissues were obtained from 35 patients ad-
mitted in the Department of Gastrointestinal Surgery,
the Affiliated Hospital of Nanjing Medical University
(Changzhou Second People’s Hospital). The project was
approved by the Research Ethics Committee of Nanjing
Medical University, and a written consent was obtained
from each patient enrolled in this study. All tissue sam-
ples were processed for storage in liquid nitrogen and
H&E staining for pathological analysis.Cell lines and cell culture
Human gastric cancer cell lines SGC-7901, BGC-823,
AGS, non-malignant gastric cell line GES-1, and HEK293T
cells were purchased from the Cell Resource Center,
Shanghai Institute of Biochemistry and cell Biology, the
Chinese Academy of Sciences. These cells were maintained
in a humidity incubator at 37°C, 5%CO2 and SGC-7901,
BGC-823, and GES-1 cells were cultured in RPMI1640
medium, HEK293T cells in DMEM, and AGS cells in
F12K medium, respectively. All culture media were supple-
mented with 10% fetal bovine serum and antibiotics.
RNA extraction and quantitative real-time PCR
Total RNA from gastric tissues or cell lines were extracted
using Trizol reagent (TaKaRa) according to the manufac-
turer’s instructions. cDNA was synthesized with the Pri-
meScript RT reagent kit (TaKaRa). Quantitative RT-PCR
was carried out with a SYBR Premix Ex Taq kit (TaKaRa)
on a 7500 real time PCR system (ABI) and analyzed with
the SDS analysis software package (version 2.0.1, Applied
Biosystems). PCR primers were obtained from Invitrogen,
and the reaction was 95°C, 10 min,followed by 40 cycles
of 95°C 15 seconds and 60°C, 1 min. The U6 snRNA was
used as an internal control. The results were presented as
fold change, calculated using the 2-△CT method, and a
ratio of expression in the tumors relative to the normal
tissues less than 1.0 was considered as low.
Vector constructs
Pri-miR-206 was amplified from normal human genomic
DNA by PCR using primers: 206-For 5′-ATAAGAATG
CGGCCGCAGATGCGGGCTGCTTCTGGA-3′ and 206-
Rev 5′-AGCTTTGTTTAAACCCTTGGTGAGGGAGTC
ATTTGC-3′. The PCR fragment was inserted into the
MSCV-P2GM vector to generate P2GM-miR-206. The
empty P2GM vector was used as the control.
Cell transfection
Plasmid transfection of SGC-7901 cells were carried out
using lipofectamine 2000 (invitrogen), and stable clones
carrying P2GM-miR-206 or the empty vector were se-
lected for puromycin resistance (10 μg/ml). MiR-206 and
negative control mimics were obtained from Ribobio
(Guangzhou, China) and transfection of mimics in SGC-
7901 cells was done using Oligofectamine (Invitrogen).
Briefly, SGC-7901 cells plated out 1 day earlier were trans-
fected with 100 nm of miR-206 or control mimics at
reaching 50% confluence. After 48 h, the cells were pro-
cessed for further analysis.
Cell proliferation assay
MTT assay was used to estimate the proliferative rate of
SGC-7901 cells. Briefly, SGC-7901 cells were trypsinzed
2 days after transfection and reseeded at 2.5 × 103 cells
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2-yl)-2, 5-diphenyl-tetrazoliumbromide) was added to the
culture medium at specified intervals for xx hrs, and the
absorbance at 490 nm was measured with a spectro-
photometer. Each assay was performed in triplicates and
repeated three times independently.
Colony formation assay
Stable SCG-7901 cells carrying miR-206 or the empty
control were trypsinized and replated at 1 × 103 per well
in 6-well plates. After 14 days in culture in RPMI1640
supplemented with 10% FBS, colonies were fixed with
3.7% methanol and stained with 0.1% crystal violet.
Colonies containing at least 50 cells were scored. Each
assay was performed in triplicates.
Flow cytometry
SGC-7901 cells transfected with miR-206 mimic or
negative control were trypsinized and resuspended in 1×
binding buffer at 1 × 106 cells/ml. 100 μl of this cell sus-
pension was incubated with 5 l of FITC-Annexin V and
5 μl propridium iodide (PI) for 15 minutes in the dark.
The reaction was terminated with the addition of 400 μl
1× binding buffer and analyzed with (FACSCalibur
using the CellQuest software (Becton Dickinson). FITC-
Annexin V-positive and PI-negative cells were consi-
dered as apoptotic and the experiments were carried out
in triplicates.
Migration and invasion assays
Wound healing cell migration was assessed by measuring
the movement of cells into a acellular area created by
scraping the confluent cell lawn with a 200 μl pipette tip.
The wound closure was photographed 48 hr later under a
microscope. For transwell migration assays, 5 × 104 cells
were added into the upper chamber of the insert (BD Sci-
ence, Sparks, MD, USA), whereas 1 × 105 cells were used
for matrigel invasion assays. In these experiments, the
cells were trypsinized and resuspended in serum-free
medium before being seeded to the upper chamber. The
full culture medium containing 10% FBS was added in the
lower chamber. The cells were incubated in a humidified
incubator at 37°C for 24 h. The cells on the membrane
were fixed, stained, and counted. Each experiment was
performed in triplicates.
Xenograft tumor model
Young female athymic nude mice (6 weeks old) were
purchased from the Model Animal Research Center of
Nanjing University. Approximately 1.5 × 106 stable SGC-
7901 cells carrying P2GM-miR-206 or the empty vector
were injected subcutaneously into the lower flanks of 5
nude mice. Tumor volumes were measured every 3 days
from the sixth day post injection onward for 24 daysbefore the animals were sacrificed. The final volume and
weight were measured after the tumors were dissected.
Nude mice were manipulated and cared for according
to NIH Animal Care and Use Committee guidelines in
the Experiment Animal Center of the Nanjing Medical
University (Nanjing, Jiangsu, Province, P.R. China).Statistical analysis
Statistical analysis was performed using the SPSS soft-
ware package (SPSS Standard version 16.0, SPSS Inc).
Data were shown as mean ± SEM. The paired-samples
t-test was used in the analysis of differential miR-206 ex-
pression between tumor and normal tissues. For in vitro
and in vivo experiments, independent-samples t-test was
used for assessing the significance of difference between
the treatment and control groups. P value < 0.05 was
considered as statistically significant.Results
Down-regulation of miR-206 correlates with human
gastric cancer tumorigenesis, invasion, and metastasis
In a genome wide survey for microRNA expression, we
previously identified several members of the myomiR fa-
mily, namely miR-1/133a and miR-133b/206, whose levels
were reduced in a neuroectodermic cancer (unpublished
results). These microRNAs were primarily known to func-
tion in myogenic differentiation and, to a lesser degree,
the tumorigenesis of pediatric cancers. To explore if these
myomiRs might also have a role in the tumorigensis of
common cancers in the adult, we examined their expres-
sion levels by real-time stem-loop RT PCR quantification
in a cohort of freshly resected gastric tumors and their
matching normal tissues, and found that the median ratio
of miR-206 relative to U6 snRNA of the 35 tumors was
4-fold lower than that of the normal tissues (Figure 1A).
Pair-wise comparison indicated that over 85% of tumors
showed greater than 2-fold reduction of miR-206 expres-
sion compared to their matching controls, with only two
pairs showing increase (Figure 1B). Expression of miR-206
was also decreased in a number of human gastric cancer
cell lines, including SGC-7901, BGC-823, MGC-803, and
AGS cells, compared to that in GES-1 normal gastric cells
(Figure 1C). Clinicopathological records of these tumors
showed that the reduction of miR-206 expression was
significantly associated with lymphatic metastasis, local in-
vasion, and the TNM malignancy staging, but not with
age, gender, tumor size or location (Table 1). These data
imply that miR-206 may normally exert an inhibitory con-
trol on gastric tumorigenesis, invasion, and metastasis.
Expression of miR-133a was also found to be down-
regulated in the tumors by the above criteria (Additional
file 1: Figure S1), but expression of miR-1, whose genes
are clustered with those encoding miR-133a [14], was not
Figure 1 Reduced levels of miR-206 expression in gastric cancer
tissues and cell lines. (A) Distribution of miR-206 expression in a
cohort of 35 human GC and noncancerous tissues by qRT-PCR. The
endogenous U6 RNA was used as the internal control. (B) Pairwise
comparison of miR-206 expression between GC and matching
non-cancerous tissues showing miR-206 expression was reduced in
86% (30/35) of the sample pairs. (C) Relative expression of miR-206
in four GC cell lines and a normal gastric cell line (GES-1).




miR-206 (mean ± SEM)
P-value
Gender
Male 21 0.49 ± 0.07 0.32
Female 14 0.40 ± 0.06
Age (years)
≥60 19 0.45 ± 0.05 0.93
<60 16 0.46 ± 0.09
Diameter (cm)
≥5 13 0.46 ± 0.09 0.90
<5 22 0.45 ± 0.05
Location
Middle and proximal third 23 0.47 ± 0.06 0.65
Distal third 12 0.42 ± 0.07
Degree of differentiation
well and moderately 12 0.48 ± 0.07 0.70
Poorly 23 0.44 ± 0.07
Local invasion
T1 + T2 10 0.65 ± 0.07 0.01
T3 + T4 25 0.37 ± 0.05
Lymph node metastasis
NO 14 0.57 ± 0.06 0.04
YES 21 0.38 ± 0.07
TNM stage
I + II 12 0.60 ± 0.07 0.02
III + IV 23 0.38 ± 0.06
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a unique gene, it was chosen for further analysis.
MiR-206 inhibits gastric cancer cell growth
To determine if miR-206 has the propensity to suppress
gastric cancer tumorigenesis, we introduced a synthetic
double stranded miR-206 mimics, 206mi, to alter the
level of total miR-206 in SGC-7901 gastric cancer cells,
which express a low level of miR-206 relative to that of
GSE-1 normal control cells (Figure 1C), and monitored
the rate of cell growth using the tetrazolium dye, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT). Stem-loop PCR confirmed the elevated level of
miR-206 in the transfected SGC-7901 cells (Figure 2A),
and results from the MTT assay indicated that the growth
rate of these cells was reduced markedly compared to that
of the cells receiving non-specific control mimics, miR-
ctrl, over a 5-day period (Figure 2B). We also generated a
pre-miR-206 expressing plasmid in the P2GM vector, and
fluorescence-activated-cell-sorting (FACs) analysis showed
Figure 2 Forced expression of miR-206 suppresses the proliferation of SGC-7901 gastric cancer cells. (A) Total levels of miR-206 in
SGC-7901 cells transfected with the miR-ctrl or the synthetic mimics of miR-206, 206mi (***P < 0.0001). (B) MTT assays for SGC-7901 cells transfected
with miR-206 mimics at a final concentration of 100 nM. Starting from 24 h post-transfection, the assays was read every 24 h for 5 consecutive days.
Results are expressed as means ± SEM from three independent experiments. (***P < 0.0001). (C) A histogram depicting cell cycle distribution of
SGC-7901 cells transiently transfected with P2GM-miR-206 or P2GM-ctrl (100 nM). The results represent the means ± SEM of three independent
experiments (*P < 0.05). (D) Cells staining positive for Annexin V-FITC and negative for PI at 48 h post-transfection were considered to have undergone
apoptosis. (E) Average apoptotic rate of three independent experiments ± SEM are shown (***P < 0.0001).
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P2GM-206 (P206) transfected compared to the P2GM
vector transfected SGC-7901 cells (Figure 2C), thus cor-
roborating the result from the above 206mi mimic ex-
periment. Artificially increasing the total level of miR-206
with 206 mi also resulted in a significant increase of apop-
tosis in 48 hrs in SGC-7901 cells over the control mimics
transfected cells as determined by flow cytometric analysis
of PI and Annexin V double uptake (Figure 2D and E).
These data indicate that miR-206 is a potent anti-prolife-
rative regulator of cultured gastric cancer cells.MiR-206 inhibits anchorage-dependent gastric cancer cell
growth and xenograft tumor formation
To examine the long term impact of miR-206 on cell
growth and colony formation, we generated a stable line
of SGC-7901 cells, P2GM-miR-206, that expresses miR-
206 from a constitutively active vector, MSCV-P2GM,
and a line of empty vector-carrying cells, P2GM-miRctrl.
First, we examined the expression level of miR-206 in
these two stable cell lines and found that miR-206 was
dramatically elevated in P2GM-miR-206 stable cell line
(Figure 3A). Then we analyzed the effect of miR-206 on
Figure 3 MiR-206 suppresses anchorage-dependent GC cell growth and xenograft tumor formation. (A) The expression level of miR-206 in
P2GM-miR-206 stable cell line and vector-carrying control stable cells (***P < 0.0001). (B) One thousand stable SGC-7901 cells of miR-206 and negative
control were plated onto 6-well plates and a colony formation assay carried out. Representative results of colony formation of P2GM-miR-control,
P2GM-miR-206. (C) The number of colonies was counted on the 14th day after seeding. Stable SGC-7901 cells of miR-206 grew to a lower density
compared to NC. The results represent the means ± SEM of three independent experiments (**P < 0.01). (D) SGC-7901 cells with stable expression of
miR-206 or not were inoculated subcutaneously into both flanks of nude mice(n = 5 per group). Representative photographs of nude mice 24 days
after inoculation are shown. (E) The mice were killed and the tumors were weighted 24 days after inoculation, the xenografts with miR-206
overexpression were significantly smaller than the control xenografts. (F) shows tumor growth curve (*P < 0.05 and **P < 0.01). (G) Tumors from
each group were weighed immediately after removal. The average tumor weight is indicated as means ± SEM (*P < 0.05).
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nized cells directly onto petri dish and visualize the cell
colonies by crystal violet staining following 14 days of cul-
ture. The results showed that the vector-carrying control
stable cells formed significantly more colonies than the
miR-206-expressing cells (Figure 3B and C). We further
injected these stable cells subcutaneously into two bila-
teral lower backs of nude mice, and monitored tumor
growth daily. Twenty-four days following the injection,
these mice were sacrificed and the tumors were excised
and weighed (Figure 3D and E). The results showed that
the average volumes of miR-206-overexpressing tumors
grew at a much slower pace than the control tumors andthe mean final weight was significantly less than that of
the controls (Figure 3F and G).
MiR-206 inhibits gastric cancer cell invasion and
migration
Reduced expression of miR-206 in locally invasive and
metastatic tumors (Table 1) suggests that this microRNA
may regulate cell migratory process. To determine if this
indeed is the case, we carried out wound-healing and
transwell migration assays using the miR-206-expressing
stable SGC-7901 cells. The results showed that ectopic
overexpression of miR-206 caused a suppression of cell
migration in SGC-7901 cells as evident in the wound-
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migration assay (Figure 4C and D). Ectopic overex-
pression of miR-206 further inhibited SGC-7901 cell in-
vasion as demonstrated by the Matrigel invasion assay
(Figure 4E and F). Hence, miR-206 displayed a suppres-
sive property in cancer cell migration and invasion as-
says in vitro.
miR-206 inhibits liver metastasis of GC in vivo
To investigate the effect of miR-206 on metastasis
in vivo, we carried out tail-vein injection of P2GM-miR-
206 and the vector alone P2GM cells with nude mice,Figure 4 MiR-206 suppresses GC cell migration and invasion in vitro.
miR-control, miR-206 cells. The ectopic expression of miR-206 obviously inh
Data represent the means ± SEM of three independent experiments. (**P <
migration (C) and invasion (E) in miR-206-expressing stable SGC-7901 cells
respectively. Data represent the means ± SEM of three independent experim42 days after injection, we harvested and photographed
the livers (Figure 5A, upper panels). H&E staining of the
tissue sections indicated a 7-fold lower number of meta-
static tumor nodules per unit area in the livers injected
with P2GM-miR-206 cells than those injected with
P2GM control cells (Figure 5A, lower panels and B).
Moreover, the sizes of tumor nodules in the P2GM-
miR-206 cell-injected livers were much smaller than
those of the control group (Figure 5A). This result
strongly argues that miR-206 normally may have a
tumor suppressor role preventing metastasis of gastric
cancer cells.(A) The wound-healing assay showed different cell motilities in
ibited the migration of SGC-7901 cells. (B) shows the statistical results.
0.01). Over-expression of miR-206 significantly impeded abilities of cell
compared with negative control. (D, F) shows the statistical results
ents. (**P < 0.01, ***P < 0.0001).
Figure 5 MiR-206 inhibits liver metastasis of GC in vivo. (A) Representative macroscopic pictures of mouse liver, 42 Days after inoculation, (The
upper). Representative photographs of H&E stained spontaneous liver metastases. Magnification:10× (The lower). The results show that tumor nodules in
P2GM-miR-206 group were smaller and fewer as compared to the control group. (B) Numbers of liver metastatic loci were counted and compared
between mice bearing SGC-7901 vector control cells and SGC-7901 cells expressing miR-206. Data represent the means ± SEM, (***P < 0.0001). (C) Relative
mRNA level of putative targets of miR-206 between SGC-7901-miR-P2GM and SGC-7901-miR-206 cells. (D) The relative mRNA level of putative targets of
miR-206 between GES-1 and SGC-7901 cell lines.
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its anti-metastatic role, we searched for possible miR-206
target genes using a combination of online microRNA tar-
get acquisition tools, and cross-referenced the resulting
candidates to those that have been reported to play a role
in metastasis. In a pool of 20 of such genes, we found 9 of
them (Additional file 3: Table S1), namely STC2, HDAC4,
KLF4, IGF1R, FRS2, SFRP1, BCL2, BDNF, and K-ras, were
drastically down-regulated by miR-206 in the P2GM-miR-
206 stable cells compared to their respective levels in the
P2GM vector stable cells (Figure 5C). Some of these miR-
206 target genes were markedly up-regulated in the paren-
tal SCG-7901 GC tumor cells compared to normal gastric
GES-1 cells (Figure 5D), suggesting a likely causal event.
Thus, miR-206 likely inhibits metastasis of GC tumor cells
through a network of regulatory genes.
Discussion
Although dysregulation of miRNAs was reported in vari-
ous types of human cancers [19], aberrant expression and
potential role of miRNAs in gastric cancers were under-
studied. Here, we demonstrate that miR-206 is frequently
downregulated in human gastric cancers and cancer cell
lines. In light of the reduced miR-206 expression reported
in several types of tumors, our results suggest that redu-
cing miR-206 expression is likely a prerequisite event intumorigenesis. This requirement was made even more
relevant when we found that low levels of miR-206 were
significantly associated with lymphatic metastasis, local
invasion, and TNM stage. This notion was corroborated
by the outcomes of ectopic expression of miR-206 in GC
cancer cell line SCG-7901, which showed that miR-206 re-
pressed GC cell proliferation, colony formation, invasion,
and migration. Finally, the ability of miR-206 to suppress
metastasis of SCG-7901 cells into the liver provided a
clear explanation for the correlation between low levels of
miR-206 and invasive and metastatic gastric cancers.
Recently STC2 was identified as a predictive marker for
lymph node metastasis in esophageal squamous-cell car-
cinoma [20]. Expression of TrkB and BDNF is associated
with poor prognosis in NSCLC patients[21]. Several stu-
dies have reported that IGF1R expression is elevated in
metastatic prostate cancer and hormone resistance pro-
gression [22,23]. BCL2 expression in primary prostate
cancer is a marker for poor prognosis, with an increased
risk for recurrence [24]. What is said above suggesting a
common oncogenic role in human cancer. Further we
identified STC2, HDAC4, KLF4, IGF1R, FRS2, SFRP1,
BCL2, BDNF and K-ras as putative functional targets of
miR-206, as part of them were talked above. Taken to-
gether, our findings suggest a tumor suppressor role of
miR-206 in human gastric cancer.
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been reported in several cancers: miR-206 was first found
to be downregulated in ERalpha-positive human breast
cancer tissues and introduction of miR-206 into estrogen-
dependent MCF-7 breast cancer cells inhibits cell growth
in a dose- and time-dependent manner [25]. Moreover,
miR-206 could promote myogenic differentiation and
block tumor growth in xenografted mice by downre-
gulating the product of the MET proto-oncogene: Met
tyrosine-kinase receptor [26]. Yan also found that inhibi-
tion of miR-206 function could contribute to aberrant cell
proliferation and migration, leading to rhabdomyosarcoma
development by suppression of C-Met [16]. Meanwhile
miR-206 could be used to inhibit HeLa cell migration and
focus formation by inhibiting both Notch3 protein and
mRNA [27]. Furthermore, miR-206 was downregulated in
high metastasis lung cancer compared to low metastasis
tumors and normal lung tissues, overexpression of miR-
206 inhibited migration and invasion of lung cancer cells
[18]. MiR-206 expression decreased in estrogen receptor-α
(ERα)-positive endometrial endometrioid adenocarcinoma
(EEC) and its overexpression inhibited ERα-dependent
proliferation, impaired invasiveness and induced cell cycle
arrest of ERα-positive EEC cell lines [28]. All these findings
indicated that miR-206 may play a tumor suppressor role
in various cancers.
Metastasis contributes to most cancer related deaths.
GC ranks as the second leading cause of cancer-related
death worldwide because its high rate of metastasis, in-
cluding lymph node, peritoneum, liver etc. Especially the
5-year survival rate of gastric tumor with liver metasta-
ses does not exceed 10% and the median survival with-
out any treatment is about 3 to 5 months [29]. Multiple
genes played a pivotal role in GC metastasis: such as the
overexpression of insulin-like growth factor receptor-I
(IGF-IR) and the activation of its signaling pathways
both play critical roles in the development and progres-
sion of gastric cancer. Knocking-down of Spl expression
by small inhibitory RNA led to decreased IGFIR expres-
sion and attenuated growth and metastasis of gastric
cancer cells [30], otherwise, IGF1R can be downregu-
lated by miR-7 and significantly reduced GC cell migra-
tion and invasion [31]. Adachi found that blockade of
IGF-IR is involved in the suppression of cancer cell inva-
sion through downregulation of matrilysin [32]. Those
metastasis related genes may provide us new therapeutic
targets for GC treatment, as surgical operation can not
solve all problems. A surgical resection of liver metasta-
sis from gastric cancer is rarely indicated, because liver
metastasis is often associated with extrahepatic disease,
such as peritoneal dissemination, lymph node metastasis,
and direct cancer invasion of other organs [33]. Re-
current tumors usually develop in the liver following a
hepatic resection for gastric metastases (62%–79%) [34].The efficacy of adjuvant chemotherapy after resection of
liver metastases has not been fully evaluated. will assist
in the development of new targeted therapies and per-
haps best define those patients with potentially chemo-
sensitive tumors. Our findings may have a therapeutic
potential to suppress GC metastasis.
Conclusion
In conclusion, we show, for the first time, that miR-206
is down-regulated in gastric cancer, overexpression of
miR-206 decrease the proliferation and metastatic po-
tential of gastric cancer cells in vitro and vivo. Down-
regulation of miR-206 was particularly significant in
tumors with lymphatic metastasis, local invasion, and
advanced TNM staging. We also identified a likely novel
mechanism of miR-206 to suppress tumor growth and
metastasis by inhibiting the protein translation of STC2,
HDAC4, KLF4, IGF1R, FRS2, SFRP1, BCL2, BDNF, and
K-ras. Thus, miR-206 functions as a tumor suppressor in
gastric cancer. The identification of miR-206 and its tar-
get gene in gastric cancer may help in understanding the
potential molecular mechanisms of gastric cancer deve-
lopment and may have diagnostic as well as therapeutic
value in the future.
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